Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

25.08
-0.2700-1.07%
Pre-market: 25.380.2960+1.18%09:16 EDT
Volume:2.16M
Turnover:54.13M
Market Cap:3.14B
PE:116.43
High:25.67
Open:25.49
Low:24.73
Close:25.35
52wk High:31.77
52wk Low:15.10
Shares:125.07M
Float Shares:111.18M
Volume Ratio:1.19
T/O Rate:1.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:14.22
PE(LYR):-197.70

Loading ...

Arcutis Biotherapeutics price target raised to $35 from $34 at Guggenheim

TIPRANKS
·
Feb 27

Stock Track | Arcutis Biotherapeutics Soars 5.15% Intraday on Strong Earnings and Analyst Upgrades

Stock Track
·
Feb 27

Arcutis Biotherapeutics Is Maintained at Buy by Needham

Dow Jones
·
Feb 26

Stock Track | Arcutis Biotherapeutics Soars 5.78% in Pre-Market on Analyst Upgrades Following Strong Earnings

Stock Track
·
Feb 26

Arcutis Biotherapeutics, Inc. : H.c. Wainwright Raises Target Price to $34 From $30

THOMSON REUTERS
·
Feb 26

Arcutis Biotherapeutics Inc : TD Cowen Raises Target Price to $35 From $30

THOMSON REUTERS
·
Feb 26

Stock Track | Arcutis Biotherapeutics Soars 5.52% After-Hours on Strong Q4 Earnings Beat and Raised 2026 Guidance

Stock Track
·
Feb 26

Stock Track | Arcutis Biotherapeutics Soars 5.07% After-Hours on Strong Q4 Earnings Beat and Raised 2026 Guidance

Stock Track
·
Feb 26

Arcutis Biotherapeutics files automatic mixed securities shelf

TIPRANKS
·
Feb 26

BRIEF-Arcutis Biotherapeutics Inc Files For Mixed Shelf

Reuters
·
Feb 26

BRIEF-Arcutis Announces Fourth Quarter And Full Year 2025 Financial Results

Reuters
·
Feb 26

Arcutis Biotherapeutics Inc Files for Mixed Shelf; Size Not Disclosed- SEC Filing

THOMSON REUTERS
·
Feb 26

Arcutis Q4 revenue rises 84% on ZORYVE sales, raises FY guidance

Reuters
·
Feb 26

Arcutis Biotherapeutics Q4 EPS $0.13 Beats $0.10 Estimate, Sales $129.503M Beat $113.055M Estimate

Benzinga Earnings
·
Feb 26

Arcutis posts FY 2025 ZORYVE net product revenue of USD 372.1 million up 123%

Reuters
·
Feb 26

Arcutis Biotherapeutics Inc - Raises 2026 Sales Guidance to $480-$495 Mln

THOMSON REUTERS
·
Feb 26

Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

THOMSON REUTERS
·
Feb 26

U.S. Earnings Preview: After Market Close Feb. 25

Dow Jones
·
Feb 26

Arcutis announces Max Homa joins ‘Free to Be Me’ campaign

TIPRANKS
·
Feb 24